Investor Presentaiton slide image

Investor Presentaiton

Continuous improvement of Shield IVD - best-in-class blood-based CRC screening INVESTOR 20 DAY 23 TM shield GUARDANTâ„¢ *Pending successful regulatory-grade data readout for V2. Submit V2 supplemental PMA following approval of Shield* Potential for V2 approval in 2025 127
View entire presentation